Adjuvant Treatment for pT3N0 Signet Ring Cell Adenocarcinoma of the Ascending Colon
For a patient with signet ring cell adenocarcinoma of the ascending colon, pT3N0 (stage IIA), after curative surgery, adjuvant chemotherapy should NOT be routinely offered unless high-risk features are present, in which case 6 months of fluoropyrimidine monotherapy (capecitabine or 5-FU) is recommended.
Risk Stratification is Critical
The 2022 ASCO guidelines clearly state that ACT should not routinely be offered to patients with stage IIA (T3) tumors who have at least 12 sampled lymph nodes and lack high-risk features 1. However, signet ring cell histology itself represents poor/undifferentiated tumor grade, which is explicitly listed as a high-risk feature 1.
High-Risk Features to Assess:
- Poorly differentiated/undifferentiated histology (signet ring qualifies)
- Lymphovascular invasion (LVI)
- Perineural invasion (PNI)
- <12 lymph nodes examined
- T4 tumor stage
- Intestinal obstruction or perforation
- Grade BD3 tumor budding
Treatment Algorithm
If ONLY Signet Ring Histology (No Other High-Risk Features):
Offer 6 months of fluoropyrimidine monotherapy (capecitabine preferred, or 5-FU-based regimen) 1, 2. The Pan-Asian ESMO guidelines specifically recommend fluoropyrimidine therapy for intermediate-risk stage II disease (MSI-proficient with any risk factor) 2.
If Multiple High-Risk Features Present (e.g., Signet Ring + LVI/PNI):
Consider adding oxaliplatin (3 months of CAPOX or 6 months of FOLFOX) through shared decision-making 1, 2. The Pan-Asian guidelines note that patients with multiple intermediate-risk factors should be considered for oxaliplatin-containing regimens 2.
Critical Caveat - MSI Status:
Check mismatch repair (MMR)/microsatellite instability (MSI) status immediately. If the tumor is MMR-deficient/MSI-high, do NOT offer adjuvant chemotherapy as these patients do not benefit from fluoropyrimidine-based therapy 1. The exception: if you decide to treat an MSI-high tumor due to multiple high-risk features, use oxaliplatin-containing chemotherapy 1.
Evidence Specific to Signet Ring Cell Carcinoma
Recent data from 2024 shows that adjuvant therapy did NOT improve survival in stage II signet ring cell carcinoma (52.1 vs. 53.1 months; P=0.694), though it did benefit stage III disease 3. A 2025 systematic review confirmed that the benefit in stage II signet ring cell carcinoma remains unclear 4. This reinforces the guideline recommendation against routine treatment but supports consideration in truly high-risk cases.
Timing and Practical Considerations
- Start adjuvant therapy within 8 weeks of surgery - this timing is critical for efficacy 2
- For fluoropyrimidine monotherapy: 6 months duration 1, 2
- If using CAPOX: 3 months is acceptable for intermediate-risk stage II 2
- If using FOLFOX: 6 months duration 2
Common Pitfalls to Avoid
- Do not automatically treat all stage II patients - the harms may outweigh benefits in low-risk disease 1
- Do not add oxaliplatin routinely - reserve for truly high-risk features or through careful shared decision-making given the peripheral neuropathy risk 1
- Do not forget MSI testing - this completely changes the treatment recommendation 1
- Do not use 5-FU bolus regimens (Mayo Clinic protocol) - these have unfavorable toxicity profiles and should be avoided 5
The Bottom Line
In your specific case of pT3N0 signet ring cell carcinoma with adequate lymph node sampling (≥12 nodes), the signet ring histology itself constitutes a high-risk feature. Offer 6 months of capecitabine or 5-FU-based therapy after confirming MSI-proficient status. If additional high-risk features are present (LVI, PNI, <12 nodes), escalate to 3 months of CAPOX through shared decision-making, weighing the patient's fitness and tolerance for oxaliplatin-related toxicity against the modest additional benefit.